[Revised criteria for the early diagnosis of diabetic nephropathy]. 2005

Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
Japanese Society of Nephrology.

The Diabetic Nephropathy Committee recommends the use of revised criteria for the early diagnosis of diabetic nephropathy in Japan. The new criteria are as follows: 1) Urinary albumin should be determined by immunoassay using a morning spot urine sample in diabetic patients without proteinuria or with dipstick-positive(+ 1) proteinuria. 2) A urinary albumin-to-creatinine ratio ranging from 30 to 299 mg/ gCr in 2 or more of 3 specimens may be diagnosed as microalbuminuria. 3) Two alternatives, i.e. the urinary albumin excretion rate of 30-299 mg/24hr in 24hr urine collection or 20-199 microg/min in timed urine collection can be used to detect microalbuminuria. 4) Renal hypertrophy and elevated urinary type IV collagen may indicate the existence of diabetic renal disease. 5) Microalbuminuria originating in non-diabetic diseases should be excluded.

UI MeSH Term Description Entries
D006984 Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA). Hypertrophies
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000419 Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES. Albuminurias
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
April 2016, Nihon rinsho. Japanese journal of clinical medicine,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
March 2003, Recenti progressi in medicina,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
October 1996, Diabetes/metabolism reviews,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
January 2017, Current diabetes reviews,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
January 1993, Nephron,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
December 2012, Diabetes,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
November 1990, Anales espanoles de pediatria,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
March 1996, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
January 1991, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Shigeki Inomat, and Masakazu Haneda, and Tatsumi Moriya, and Shigehiro Katayama, and Yasuhiko Iwamoto, and Hideto Sakai, and Yasuhiko Tomino, and Seiichi Matsuo, and Yasushi Asano, and Hirofumi Makino, and
December 1976, Journal of the Iowa Medical Society,
Copied contents to your clipboard!